Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER: UK API 34460 Insp GMP 34460/720129-0005 [H]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER (1),(2)

Part 1

Issued following an inspection in accordance with:

Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following:

The Manufacturer: YONSUNG FINE CHEMICALS COMPANY LIMITED

Site address: YONSUNG FINE CHEMICALS COMPANY LIMITED, 207 SUJEONG-RO, JANGAN-MYEON, HWASEONG-SI, GYEONGGI-DO, KR-18581, SOUTH KOREA

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Regulation 17 Part 16 of The Human Medicines Regulations 2012 (SI 2012/1916)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 26/11/2012, it is considered that it complies with

• The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection:

- [1000003182] ALPROSTADIL
- [2000007625] CISATRACURIUM BESYLATE
- [2000007668] EPOPROSTENOL SODIUM
- [1000009076] MISOPROSTOL
- [2000009151] TREPROSTINIL SODIUM
- [4000013362] PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

- [2000008448] ATRACURIUM BESYLATE
- [2000007876] TAMSULOSIN HYDROCHLORIDE
- [4000012823] MISOPROSTOL HPMC 1% DISPERSION
- [1000003257] LATANOPROST
- [1000016469] LIMAPROST
- [1000000645] BIMATOPROST
- [1000007990] BROMFENAC
- [1000000660] TRAVOPROST
- [2000007274] IMIDAPRIL HYDROCHLORIDE
- [2000014372] BERAPROST SODIUM
- [1000007347] CABERGOLINE
- [2000007863] LEVOCABASTINE HYDROCHLORIDE
- [1000003754] ILOPROST

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

ALPROSTADIL

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

3.5 General Finishing Steps

3.5.1 Physical Processing Steps

Drying

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

3.6.2 Microbiological testing (excluding sterility testing)

CISATRACURIUM BESYLATE

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance


3.5 General Finishing Steps

3.5.1 Physical Processing Steps

Drying

3.5.2 Primary Packaging

3.5.3 Secondary Packaging



3.6 **Quality Control Testing** 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing (excluding sterility testing) **EPOPROSTENOL SODIUM** 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates 3.1.2 Manufacture Of Crude Active Substance General Finishing Steps 3.5 3.5.1 Physical Processing Steps Drying 3.5.2 Primary Packaging 3.5.3 Secondary Packaging **Quality Control Testing** 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing (excluding sterility testing) **MISOPROSTOL** 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates 3.1.2 Manufacture Of Crude Active Substance 3.5 General Finishing Steps 3.5.1 Physical Processing Steps Drying 3.5.2 Primary Packaging 3.5.3 Secondary Packaging 3.6 **Quality Control Testing** 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing (excluding sterility testing) TREPROSTINIL SODIUM Manufacture of Active Substance by Chemical Synthesis

	o manaradaro en nomo esperance intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
	LODIDE MONOLIVODATE
PRAMIPEXOLE DIHYDROCH	
3.1	Manufacture of Active Substance by Chemical Synthesis
M_{II}	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps Drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
ATRACURIUM BESYLATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
VK I	3.5.1 Physical Processing Steps
	Drying

3.1.1 Manufacture Of Active Substance Intermediates

	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
TAMSULOSIN HYDROCHLOR	RIDE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
	o. 1.2 Walturacture of Ordue Active Substance
3.5	General Finishing Steps
-1/1	3.5.1 Physical Processing Steps
	Drying
	3.5.2 Primary Packaging
11.	
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
MISOPROSTOL HPMC 1% DIS	SPERSION
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
	3.1.2 Wallulacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
	oloro Coomany Labraging
3.6	Quality Control Testing
V. V.	3.6.1 Physical / Chemical testing

3.5.2 Primary Packaging

LATANOPROST	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
LIMAPROST	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps Drying
	3.5.2 Primary Packaging
	4/),
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
BIMATOPROST	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates

3.6.2 Microbiological testing (excluding sterility testing)

3.1.2 Manufacture Of Crude Active Substance

3.5	General Finishing Steps
	3.5.1 Physical Processing Steps Drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
BROMFENAC	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
TRAVOPROST	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Drying
14.	3.5.2 Primary Packaging
V.	3.5.3 Secondary Packaging
W 17.	
3.6	Quality Control Testing

3.6.1	Physical /	Chemical	testina

3.6.2 Microbiological testing (excluding sterility testing)

IMIDAPRII	HYDROCHL	ORIDE
IIVIIDAFKIL	T T D K O C T L	URIDE

IMIDAPRIL HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Drying
	3.5.2 Primary Packaging
XY	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
1/1,	
	3.6.2 Microbiological testing (excluding sterility testing)
BERAPROST SODIUM	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
CABERGOLINE	

Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates

	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
LEVOCABASTINE HYDROCHI	OPIDE
3.1	Manufacture of Active Substance by Chemical Synthesis
5.1	3.1.1 Manufacture Of Active Substance Intermediates
VK.	5.1.1 Wandacture of Active Substance intermediates
M_{II}	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing (excluding sterility testing)
ILOPROST	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
4 4 1	Draina

3.5.2 Primary Packaging

3.6

Quality Control Testing

3.6.1 Physical / Chemical testing

3.6.2 Microbiological testing (excluding sterility testing)

Restrictions or Remarks

GMP Certificate re-issued due to change of allocated address of the site- no further inspection conducted.

17/02/2014 Name and signature of the authorised person of the Competent Authority of United Kingdom

Confidential

Medicines and Healthcare products Regulatory Agency

Tel: Confidential